Publications by authors named "Allan Tenorio"

Claim this Profile
F
Fostemsavir resistance in clinical context: a narrative review.
Jonathan M Schapiro, Rolf Kaiser, Mark Krystal, Chris M Parry, Allan R Tenorio

Ther Adv Infect Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The sensitivity of HIV-1 gp120 polymorphs to inhibition by temsavir correlates to temsavir binding on-rate.
David Wensel, Margaret Gartland, Jagadish Beloor, Kartika N Shetty, Jana Wolf, Allan Tenorio

Antiviral Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study.
Andrew Clark, Manyu Prakash, Shiven Chabria, Amy Pierce, Jose R Castillo-Mancilla, Allan R Tenorio

Open Forum Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
Margaret Gartland, Eugene Stewart, Nannan Zhou, Zhufang Li, Ronald Rose, Allan R Tenorio

Antiviral Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.
Josep M Llibre, Judith A Aberg, Sharon Walmsley, Juan Velez, Carlos Zala, Allan R Tenorio

Front Immunol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
Judith A Aberg, Bronagh Shepherd, Marcia Wang, Jose V Madruga, Fernando Mendo Urbina, Allan R Tenorio

Infect Dis Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
Emma Guttman-Yassky, Jacob P Thyssen, Jonathan I Silverberg, Kim A Papp, Amy S Paller, Allan R Tenorio

J Allergy Clin Immunol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Growth analysis among adolescents with moderate-to-severe atopic dermatitis receiving upadacitinib in combination with topical corticosteroids in Japan: A case study series from a phase 3, randomized, controlled trial (Rising Up).
Toshiaki Tanaka, Takuya Sasaki, Kimitoshi Ikeda, Jianzhong Liu, Allan R Tenorio

World Allergy Organ J· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
Eric L Simpson, Kim A Papp, Andrew Blauvelt, Chia-Yu Chu, H Chih-Ho Hong, Allan R Tenorio

JAMA Dermatol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment.
Karam Mounzer, Laurence Brunet, Christina M Wyatt, Jennifer S Fusco, Vani Vannappagari, Allan R Tenorio

AIDS· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
Jean van Wyk, Mounir Ait-Khaled, Jesus Santos, Stefan Scholten, Michael Wohlfeiler, Allan R Tenorio

J Acquir Immune Defic Syndr· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Emma Guttman-Yassky, Henrique D Teixeira, Eric L Simpson, Kim A Papp, Aileen L Pangan, Allan R Tenorio

Lancet· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Jean van Wyk, Faïza Ajana, Fiona Bisshop, Stéphane De Wit, Olayemi Osiyemi, Allan R Tenorio

Clin Infect Dis· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, Jihad Slim, Vicenç Falcó, Allan R Tenorio

J Acquir Immune Defic Syndr· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb

PLoS One· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Pedro Cahn, Juan Sierra Madero, José R Arribas, Andrea Antinori, Roberto Ortiz, Allan R Tenorio

J Acquir Immune Defic Syndr· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Kelly E Dooley, Richard Kaplan, Noluthando Mwelase, Beatriz Grinsztejn, Eduardo Ticona, Allan R Tenorio

Clin Infect Dis· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
Teodora Pene Dumitrescu, Kavita Peddiraju, Caifeng Fu, Kalpana Bakshi, Shui Yu, Allan R Tenorio

Clin Pharmacol Drug Dev· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants.
Ridhi Parasrampuria, Susan L Ford, Yu Lou, Caifeng Fu, Kalpana K Bakshi, Allan R Tenorio

Clin Pharmacol Drug Dev· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls.
Jafar Sadik B Shaik, Susan L Ford, Yu Lou, Zhiping Zhang, Kalpana K Bakshi, Allan R Tenorio

Clin Pharmacol Drug Dev· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir.
Parul Patel, Susan L Ford, Yu Lou, Kalpana Bakshi, Allan R Tenorio

Clin Pharmacol Drug Dev· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, Andrea Antinori, Roberto Ortiz, Allan R Tenorio

Lancet· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects.
Mark Johnson, Roxanne C Jewell, Amanda Peppercorn, Elizabeth Gould, Jianfeng Xu, Allan R Tenorio

Pharmacol Res Perspect· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
Anthony R Cillo, Benedict B Hilldorfer, Christina M Lalama, John E McKinnon, Robert W Coombs, Allan R Tenorio

AIDS· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery.
David L Pitrak, Richard M Novak, Randee Estes, Jean Tschampa, Christina D Abaya, Allan R Tenorio

AIDS Res Hum Retroviruses· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis